RxDoctor Payments Data

Kristen Middleton

Family · Rocky Mount, NCNPI 1831648609

Payments from drug & device makers

$1,224in general payments, 2019–2025

Across 53 payments — averaging $23.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$428
  • GSK$335
  • Amgen$189
  • Abbott$42
  • Sanofi-aventis U.S. LLC$41
  • Bayer$41
  • plus $148 from 8 others

What the payments were for

  • Food & beverage$1,20498%
  • Education$202%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,224 in reported general payments places this provider in the 70th percentile of 4,522 family providers in North Carolina.

See all family providers in North Carolina

Medicare billing

Part B allowed, 2024
$61,109
Medicare patients
136
Services billed
872

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide98$108,628
EliquisApixaban65$60,606
JardianceEmpagliflozin38$50,750
FarxigaDapagliflozin Propanediol71$47,588
MounjaroTirzepatide41$43,018
LinzessLinaclotide20$20,514
RexultiBrexpiprazole12$17,756
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$10,996
XareltoRivaroxaban13$10,310
Lantus SolostarInsulin Glargine,hum.Rec.Anlog45$5,091
Atorvastatin Calcium623$4,965
Gabapentin210$3,698
Omeprazole209$3,361
Amlodipine Besylate431$2,299
Albuterol Sulfate HfaAlbuterol Sulfate55$1,814

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$11$108,62898 claims
Boehringer IngelheimJardiance$33$50,75038 claims
AstraZenecaFarxiga$428$47,58871 claims
Lilly USA, LLCMounjaro$11$43,01841 claims
AbbVieLinzess$15$20,51420 claims
GSKTrelegy Ellipta$335$10,99617 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,522 family providers in North Carolina.

Other family in Rocky Mount

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →